MedTrace Logo

to Assess the Safety of Ga68-Dolacga Injection in Healthy Volunteers

NCT03908957 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 12

Last updated 2020-02-13

No results posted yet for this study

Summary

This is a phase 1 study to evaluate the safety of Ga68-Dolacga Injection in healthy volunteers and to assess the normal reference range and inter-individual variability of the Ga68-Dolacga Injection in estimating liver reserve in healthy volunteers.

Conditions

  • Safety Issues

Interventions

DRUG

Ga68-Dolacga Injection

Ga68-Dolacga Injection, 3.5±0.25 mCi, single dose iv

Sponsors & Collaborators

  • National Atomic Research Institute, Taiwan

    lead OTHER

Principal Investigators

  • Yao-Ming Wu, MD · National Taiwan University Hospital

Study Design

Allocation
NA
Purpose
DIAGNOSTIC
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
20 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2019-02-12
Primary Completion
2019-08-09
Completion
2019-08-09
FDA Drug
Yes

Countries

  • Taiwan

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03908957 on ClinicalTrials.gov